English Overview
We are delighted to invite you to the next ONCOLOGY DIALOGUE webinar and live Q&A session where speakers will discuss metastatic Breast Cancer and CDK 4/6 inhibitors as a molecule, clinical cases, and some key data patients at high risk of progression
This Activity for
- Resident / Fellow
- Physician
- Clinical Pharmacy
What I will learn?
- Defining HR+ HER2- MBC patients with high risk factors
- which CDK 4 & 6 inhibitor to select
- Managing CDK 4/6 inhibitors AEs
- which CDK 4 & 6 inhibitor to select
- Managing CDK 4/6 inhibitors AEs
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Not All CDK 4&6 Inhibitors are the Same Certificate
Certificate |
Certificate | Free |
VAT 15% Included
